NCT04111432View on ClinicalTrials.gov

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines

PHASE4CompletedINTERVENTIONAL
Enrollment

372

Participants

Timeline

Start Date

July 26, 2019

Primary Completion Date

November 25, 2019

Study Completion Date

March 25, 2020

Conditions
Hand, Foot and Mouth Disease
Interventions
BIOLOGICAL

Concomitant administration of EV71vaccine with EPI vaccines

The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.# the MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.

BIOLOGICAL

Single injection of EPI vaccine

The MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.

BIOLOGICAL

EV71 Vaccine only

The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.

Trial Locations (1)

725000

Hanbin District Center for Disease Control and Prevention, Ankang

All Listed Sponsors
collaborator

Shaanxi Provincial Center for Disease Control and Prevention

OTHER

lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT04111432 - Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines | Biotech Hunter | Biotech Hunter